| Completed | A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell ALK-positive Advanced NSCLC | Phase 2 | 2019-01-31 |
| Terminated | An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associat Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL | — | 2018-03-02 |
| Completed | ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies | Phase 3 | 2016-05-26 |
| Terminated | A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia Chronic Phase Chronic Myeloid Leukemia | Phase 3 | 2015-12-31 |
| Completed | A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK) Carcinoma, Non-Small-Cell Lung | Phase 2 | 2014-06-04 |
| Completed | A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumo GIST | Phase 2 | 2013-06-05 |
| Completed | A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Phase 1 / Phase 2 | 2012-08-31 |
| Terminated | Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) Chronic Myeloid Leukemia | Phase 3 | 2012-06-01 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | 2011-09-20 |
| Completed | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia | Phase 2 | 2010-09-30 |
| Completed | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies Chronic Myelogenous Leukemia, Hematologic Malignancies | Phase 1 | 2008-06-01 |
| No Longer Available | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies | — | — |
| Approved For Marketing | Expanded Access Program of Ponatinib Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | — | — |